Brief: Paratek Pharmaceuticals Announces Additional Funding To Advance Development Of Nuzyra
27/09/2021 22:19
Sept 27 (Reuters) - Paratek Pharmaceuticals Inc PRTK.O :
* PARATEK PHARMACEUTICALS ANNOUNCES ADDITIONAL FUNDING UNDER
THE
BARDA CONTRACT TO ADVANCE THE DEVELOPMENT OF NUZYRA®
(OMADACYCLINE) FOR POST-EXPOSURE PROPHYLAXIS (PEP) AND TREATMENT
OF PULMONARY ANTHRAX
* PARATEK PHARMACEUTICALS INC - ADDITIONAL ABOUT $19 MILLION
FUNDING FOR EXPANDED ANTHRAX PEP DEVELOPMENT PROGRAM
* PARATEK PHARMACEUTICALS INC - BARDA CONTRACT NOW VALUED AT
UP TO
ABOUT $304 MILLION
Source text for Eikon: ID:nGNX40Kyvh
Further company coverage: PRTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million